🇪🇺 6MP in European Union

EMA authorised 6MP on 9 March 2012

Marketing authorisations

EMA — authorised 9 March 2012

  • Application: EMEA/H/C/002022
  • Marketing authorisation holder: Lipomed GmbH
  • Local brand name: Xaluprine (previously Mercaptopurine Nova Laboratories)
  • Indication: Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.
  • Status: approved

Read official source →

EMA — authorised 18 January 2013

  • Application: EMEA/H/C/002501
  • Marketing authorisation holder: Only For Children Pharmaceuticals
  • Local brand name: Loulla
  • Indication: Treatment of acute lymphatic leukemia
  • Pathway: orphan
  • Status: withdrawn

Read official source →

6MP in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is 6MP approved in European Union?

Yes. EMA authorised it on 9 March 2012; EMA authorised it on 18 January 2013.

Who is the marketing authorisation holder for 6MP in European Union?

Lipomed GmbH holds the EU marketing authorisation.